NASDAQ:NBIXNeurocrine Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $124.76 +4.54 (+3.78 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$119.84Now: $124.76▼$124.9950-Day Range$94.37MA: $106.44▼$124.8052-Week Range$72.14Now: $124.76▼$128.29Volume1.13 million shsAverage Volume916,338 shsMarket Capitalization$11.59 billionP/E Ratio67.80Dividend YieldN/ABeta1.26 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL - Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $117.20, Neurocrine Biosciences has a potential downside of 6.1% from its current price of $124.76.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.6 Community Rank Outperform VotesNeurocrine Biosciences has received 859 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeurocrine Biosciences has received 321 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeurocrine Biosciences has received 72.80% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote “Outperform” if you believe NBIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,478,453.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions96.15% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 53.59% in the coming year, from $3.06 to $4.70 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 67.80, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.56.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 67.80, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.07.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 16.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.76 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NBIX Previous Symbol CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone858-617-7600Debt Debt-to-Equity Ratio0.71 Current Ratio6.90 Quick Ratio6.75Price-To-Earnings Trailing P/E Ratio67.80 Forward P/E Ratio40.77 P/E GrowthN/A Sales & Book Value Annual Sales$788.10 million Price / Sales14.70 Cash Flow$0.68 per share Price / Cash Flow182.96 Book Value$7.54 per share Price / Book16.55Profitability EPS (Most Recent Fiscal Year)$0.39 Net Income$37.01 million Net Margins19.90% Return on Equity37.53% Return on Assets18.29%Miscellaneous Employees585 Outstanding Shares92,860,000Market Cap$11.59 billion Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:NBIX Rates by TradingView Receive NBIX News and Ratings via Email Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions How has Neurocrine Biosciences' stock been impacted by COVID-19 (Coronavirus)? Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NBIX stock has increased by 45.2% and is now trading at $124.76. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Neurocrine Biosciences? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neurocrine Biosciences. When is Neurocrine Biosciences' next earnings date? Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Neurocrine Biosciences. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Wednesday, May, 6th. The company reported $0.82 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.56 by $0.26. The company earned $237.10 million during the quarter, compared to analyst estimates of $226.29 million. Neurocrine Biosciences had a return on equity of 37.53% and a net margin of 19.90%. The company's revenue for the quarter was up 71.3% compared to the same quarter last year. During the same period last year, the firm earned $0.29 EPS. View Neurocrine Biosciences' earnings history. What price target have analysts set for NBIX? 15 brokers have issued twelve-month price targets for Neurocrine Biosciences' stock. Their forecasts range from $88.00 to $153.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $117.20 in the next twelve months. This suggests that the stock has a possible downside of 6.1%. View analysts' price targets for Neurocrine Biosciences. Has Neurocrine Biosciences been receiving favorable news coverage? Media headlines about NBIX stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutNeurocrine Biosciences. Who are some of Neurocrine Biosciences' key competitors? Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Netflix (NFLX), Gilead Sciences (GILD), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), Trade Desk (TTD), salesforce.com (CRM) and Walt Disney (DIS). Who are Neurocrine Biosciences' key executives? Neurocrine Biosciences' management team includes the following people: Dr. Kevin C. Gorman, CEO & Director (Age 61)Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62) What is Neurocrine Biosciences' stock symbol? Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX." Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (8.22%), Capital International Investors (6.48%), Perceptive Advisors LLC (3.30%), Orbimed Advisors LLC (1.24%), Alliancebernstein L.P. (1.22%) and Geode Capital Management LLC (1.16%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View institutional ownership trends for Neurocrine Biosciences. Which institutional investors are selling Neurocrine Biosciences stock? NBIX stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Alliancebernstein L.P., 1832 Asset Management L.P., Nuveen Asset Management LLC, Victory Capital Management Inc., and Victory Capital Management Inc.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, and Stephen A Sherwin. View insider buying and selling activity for Neurocrine Biosciences. Which institutional investors are buying Neurocrine Biosciences stock? NBIX stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Sumitomo Mitsui Trust Holdings Inc., Janus Henderson Group PLC, Orbimed Advisors LLC, DSM Capital Partners LLC, Capital International Investors, Jennison Associates LLC, and GW&K Investment Management LLC. View insider buying and selling activity for Neurocrine Biosciences. How do I buy shares of Neurocrine Biosciences? Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Neurocrine Biosciences' stock price today? One share of NBIX stock can currently be purchased for approximately $124.76. How big of a company is Neurocrine Biosciences? Neurocrine Biosciences has a market capitalization of $11.59 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe. What is Neurocrine Biosciences' official website? The official website for Neurocrine Biosciences is www.neurocrine.com. How can I contact Neurocrine Biosciences? Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
